Senovia Biosciences is a clinical-stage biotechnology company developing small molecule therapeutics that restore healthy RNA splicing for neurodegenerative diseases. Their lead program, SOV202, targets TDP-43 mis-splicing in ALS and FTD and is in Phase 1 clinical trials. Another program, SOV201, addresses FUS mutations in ALS. The company targets patients with genetically defined ALS and frontotemporal dementia. Senovia raised $20 million in Series A funding in November 2024, led by Samsara BioCapital with participation from other investors. Their platform uses patient-derived models to identify splicing-correcting compounds. The therapeutics aim to treat the underlying splicing defects driving disease progression.